PI-103

Item no.	HY-10115-1mg
Manufacturer	MedChem Express
CASRN	371935-74-9
Amount	1 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Testicular & Prostate Cancer
Type	Inhibitors
Specific against	other
Purity	99.82
Citations	[1]Raynaud FI, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009 Jul;8(7):1725-39.\|[2]Park S, et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase anLeukemia. 2008 Sep;22(9):1698-706.d mTOR, has antileukemicactivity in AmL. Leukemia. 2008 Sep;22(9):1698-706.\|[3]López-Fauqued M, et al. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of melanoma cells. Int J Cancer. 2010 Apr 1;126(7):1549-61.\|[4]Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110 alpha. Cell. 2006 May 19;125(4):733-47. Acta Biomater. 2021 Jun 1;S1742-7061(21)00357-3.\|Adv Funct Mater. 2021 May 24.\|Adv Healthc Mater. 2021 Dec 8;e2101944.\|Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00608-20.\|bioRxiv. 2024 May 31:2024.05.30.596676.\|BMC Cancer. 2022 Nov 24;22(1):1211.\|Cancer Lett. 2025 Feb 27:217532.\|Cell Signal. 2024 Mar 5:118:111126.\|Cell Syst. 2020 Jan 22;10(1):66-81.e11. \|Cell Syst. 2025 Feb 26:101203.\|ChemMedChem. 2019 Nov 20;14(22):1933-1939.\|Clin Cancer Res. 2014 Nov 1;20(21):5483-95. \|Clin Cancer Res. 2020 Apr 15;26(8):2011-2021. \|Exp Eye Res. 2018 Jul;172:10-20.\|Expert Rev Anticancer Ther. 2024 Sep 10:1-12.\|Front Pharmacol. 2020 Nov 11;11:580407.\|Harvard Medical School LINCS LIBRARY\|Heliyon. 2024 May 6.\|J Transl Med. 2021 Dec 7;19(1):497.\|J Virol. 2022 Nov 23;e0145322.\|Molecules. 2020 Apr 23;25(8):1980.\|Nat Commun. 2023 Mar 28;14(1):1726.\|Oncogenesis. 2025 Mar 1;14(1):4.\|Research Square Preprint. 2022 Jul.\|cell rep methods. 2022 Jan 24;2(2):100155.\|Harvard Medical School LINCS LIBRARY
Smiles	OC1=CC(C2=NC3=C(C(N4CCOCC4)=N2)OC5=C3C=CC=N5)=CC=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Autophagy; DNA-PK; mTOR; PI3K
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	348.36
Product Description	PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy[1][2][3][4].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 10 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR
Isoform	mTORC1; mTORC2; PI3KC2α; PI3KC2β; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ; Vps34
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10115-1mg-safety-datasheet.pdf